Materiality pending
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
- Editas Medicine reported a loss of 76 cents per share in Q1 2024. - Collaboration revenue decreased to $1.1 million in Q1 from $9.8 million year-over-year. - R&D expenses increased, but G&A expenses decreased in Q1. - Editas had $376.8 million in cash as of March 31, 2024, down from $427.1 million in December 31, 2023. - Editas shares fell 11.4% on May 8 following the Q1 earnings announcement. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
- Editas Medicine reported a loss of 76 cents per share in Q1 2024.
- Collaboration revenue decreased to $1.1 million in Q1 from $9.8 million year-over-year.
- R&D expenses increased, but G&A expenses decreased in Q1.
- Editas had $376.8 million in cash as of March 31, 2024, down from $427.1 million in December 31, 2023.
- Editas shares fell 11.4% on May 8 following the Q1 earnings announcement.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.